

CURRICULUM VITAE
ELAINE H. MORRATO

CURRENT POSITION

Associate Dean for Public Health Practice, Colorado School of Public Health, University of Colorado Anschutz Medical Campus

Associate Professor (with tenure), Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado Anschutz Medical Campus

Secondary Appointment

Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus

13001 East 19th Place, Room E3311
Mail Stop B119
Aurora, CO 80045-0508
303-724-4760 (phone)
303-724-4495 (fax)
Email: elaine.morrato@ucdenver.edu

EDUCATION

- 1988 B.S. (Honors) summa cum laude, Biology/Biochemistry, Purdue University, West Lafayette, IN. Honors thesis: Spectral analysis of thermodynamic properties in non-Watson-Crick base pairing and DNA secondary structure
- 2003 M.P.H., Epidemiology, The Johns Hopkins University, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Masters Capstone Project: FDA pediatric drug policy: Characteristics of drugs granted exclusivity.
Advisor: (b) (6)
- 2006 Dr.P.H., General Epidemiology, The Johns Hopkins University, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Dissertation: Impact of nefazodone (Serzone®) hepatic risk minimization recommendations: a case study evaluation of an FDA Boxed Warning.
Advisor: (b) (6)
- 2004-2006 Pharmaceutical Outcomes Research Fellowship, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Denver, CO
Advisors: (b) (6)

CONTINUING EDUCATION

- 2010 Institute on Systems Science and Health (ISSH), Social Network Analysis Track, Mailman School of Public Health, Columbia University, New York, NY, with sponsorship from National Institutes of Health and the Centers for Disease Control and Prevention. Competitive selection.

- 2012 Kellogg Executive Education Program, Marketing and Sales Certificate, Kellogg School of Management, Northwestern University, Chicago, IL.
- 2014-2015 Leadership for Innovative Team Science (LITEs), a select senior and mid-career faculty development program, Colorado Clinical & Translational Sciences Institute, Aurora, CO.

ACADEMIC APPOINTMENTS AND POSITIONS

- 2015- Associate Dean for Public Health Practice, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO
- 2012- Associate Professor (with tenure), University of Colorado Anschutz Medical Campus, Aurora, CO
- 2006 - 2012 Assistant Professor, University of Colorado Anschutz Medical Campus, Aurora, CO
- After the Colorado School of Public Health was formed (2009 – present)
Primary Appointment, Department of Health Systems, Management & Policy, Colorado School of Public Health
- Secondary Appointment, Division of General Pediatrics, Department of Pediatrics, School of Medicine
- Secondary Appointment, Department of Clinical Pharmacy, School of Pharmacy
- Before the Colorado School of Public Health was formed (2006 – 2009)
Primary Appointment, Division of General Pediatrics, Department of Pediatrics, School of Medicine
- Secondary Appointment, Department of Preventive Medicine and Biometrics, School of Medicine
- Secondary Appointment, Department of Clinical Pharmacy, School of Pharmacy
- 2015-present Co-Director, Colorado Research and Implementation Science Program (CRISP), Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS), School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
- 2006-2014 Investigator, Children's Outcomes Research (COR) Program, School of Medicine, University of Colorado Denver, Aurora, CO
- Associate Director (2009-2013)
- Senior Methodologist (2006 – 2010)
- 2011-2013 Comparative Effectiveness Research (CER) Core Leader, jointly for the Colorado Health Outcomes and the Children's Outcomes Research Programs, School of Medicine, University of Colorado Denver, Aurora, CO

PROFESSIONAL POSITIONS

SCIENTIFIC CONSULTING SERVICES

- 2015 Operationalizing pharmaceutical risk management and risk communication planning into drug development processes. Amgen, Inc.
- 2013 Colorado All-Payer Claims Database: data validity and feasibility assessment for outcomes research. Janssen Scientific Affairs, LLC.

- 2013 Mock FDA Review Panel, Rx-to-OTC switch candidate. Merck & Co., Inc.
- 2013 Dextromethorphan Blue Ribbon Panel to review educational efforts to curb abuse among adolescents. Consumer Healthcare Products Association.
- 2006 Workshop on Pharmaceutical RiskMAP Evaluation. Merck & Co., Inc.
- 2002-2005 Health Care New Business Development, Pharmaceutical and Wellness Market Research Services, Information Resources, Inc., Chicago, IL.

U.S. FOOD AND DRUG ADMINISTRATION

- 2002-2003 Student research associate, Office of Drug Safety, U.S. Food and Drug Administration, Rockville, MD. Project: Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. Advisor: (b) (6)

PHARMACEUTICAL INDUSTRY

- 2000-2002 Section Head, Global Risk Management Team Leader, Cardiovascular New Drug Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
- 2000-2002 Section Head, Global Phase III Project Leader, Cardiovascular New Drug Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
- 1997-2000 Section Head, Global Phase IIIb/IV Project Leader, Cardiac Technical Brand Manager, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
- 1996-1997 Section Head, U.S. Launch Team Leader for Helidac® (tetracycline, metronidazole, bismuth-subsalicylate), North America Product Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
- 1994-1997 Section Head, Technical Brand Manager, Asacol® (mesalamine) and Macrobid® (nitrofurantoin monohydrate/macrocrystals), North America Product Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
- 1993-1994 Senior Scientist, Global Products Research Team Leader for Over-the Counter Cholesterol-Lowering Drugs, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
- 1992-1993 Senior Scientist, National Product Launch Team Leader, Metamucil® Sunrise Smooth Sugar-Free Regular Flavor, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
- 1988-1992 Scientist, Professional Oral Care Products, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
- 1987 Research Intern, Mammalian cell culture and pharmaceutical research, Monsanto Chemical Company, St. Louis, MO.
- 1986 Market Research Interviewer, Monsanto Agricultural Company, St. Louis, MO.

HONORS AND AWARDS

- 2015 “Best Poster” in the Spotlight Poster Session “Benefit Risk Assessment, Communication and Evaluation (BRACE)” at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA. August 22-26, 2015.
- 2013 Outstanding Reviewer Recognition for 2013, *Pharmacoepidemiology and Drug Safety*
- 2012 President’s Excellence in Teaching Award, Colorado School of Public Health, University of Colorado

- 2011 Outstanding Reviewer Recognition for 2010, *Pharmacoepidemiology and Drug Safety*
- 2010 Outstanding Reviewer Recognition for 2009, *Pharmacoepidemiology and Drug Safety*
- 2010 Top 100 poster showcased in the President's Poster Session and Reception at the 70th *Scientific Sessions of the American Diabetes Association*, Orlando, FL June 25-29, 2010.
- 2010 Featured poster in the poster tour entitled "Pediatrics – Type 1 Diabetes – Care and Outcomes" at the 70th *Scientific Sessions of the American Diabetes Association*, Orlando, FL June 25-29, 2010.
- 2008 Best research poster presented at the 2008 NCDEU (New Clinical Drug Evaluation Unit) Meeting. CME Institute, Physicians Postgraduate Press, Inc., *The Journal of Clinical Psychiatry* (October 2008)
- 2006 Delta Omega Honorary Society in Public Health, The Johns Hopkins Bloomberg School of Public Health
- 2005 Best Podium Presentation, *First Western Pharmacoeconomics Conference*, Salt Lake City, UT
- 2004 Poster Finalist, 9th *Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research*, Washington, D.C.
- 2004 Campaign for Epidemiology Award, Johns Hopkins, Bloomberg School of Public Health
- 2003 Master of Public Health Capstone Award for Outstanding Achievement, Johns Hopkins, Bloomberg School of Public Health
- 1996 Asacol Product Brand Team, Health Care Sector Outstanding Achievement Award, The Procter & Gamble Company
- 1994 Team of the Year, Sunrise Smooth Metamucil Sugar-Free Regular Flavor National Launch, Health Care Reward and Recognition Program, The Procter & Gamble Company.
- 1988 Helen B. Schleman Award for Women, top academic female graduate, Purdue University
- 1988 AWS Very Important Woman Award, top graduating female leader, Purdue University
- 1988 School of Science Outstanding Senior, Department of Biology, Purdue University
- 1987 Mortar Board Honor Society for achievements in scholarship, leadership, and service, Purdue University
- 1987 Phi Beta Kappa Society, Purdue University
- 1987 American Chemical Society Award for Outstanding Junior in Analytical Chemistry, Purdue University
- 1986 Pi Sigma Alpha National Honor Society of Political Science, Purdue University
- 1984-1985 School of Science Research Scholarship, Purdue University
- 1984 National Presidential Scholar Finalist and National Merit Scholar

PROFESSIONAL AFFILIATIONS

PROFESSIONAL SOCIETIES

- 2005- Member, International Society for Pharmacoepidemiology
- Founding member of the Benefit-Risk Assessment, Communication and Evaluation (BRACE) Special Interest Group (Aug 2012 -)

- 2007-2012 Member, American Diabetes Association
2005-2008 Member, International Society for Pharmacoeconomics and Outcomes Research

PROFESSIONAL SERVICE AND COMMITTEES

NATIONAL

- 2015- Public Health Practice Section, Association of Schools and Programs in Public Health
- 2014-2018 Member, FDA Pulmonary-Allergy Drugs Advisory Committee
- 2013- Invited temporary member, various FDA Advisory Committees
- 2015 Invited speaker, Public Workshop on Risk Evaluation and Mitigation Strategies: Understanding and Evaluating Their Impact on the Health Care Delivery System and Patient Access, Silver Spring, MD, October 5-6, 2015, Docket No. FDA-2013-N-0502
- 2015 Invited speaker, FDA meeting with the Conjoint Committee on Continuing Education Long-Acting Opioid Analgesics REMS Meeting, Accreditation Council for Continuing Medical Education Office, Washington, D.C., July 22, 2015.
- 2014 Invited participant, Conjoint Committee on Continuing Education Long-Acting Opioid Analgesics REMS Meeting, Accreditation Council for Continuing Medical Education Office, Chicago, IL, February 24, 2014.
- 2013 Invited participant, Expert Workshop on Strengthening Risk Evaluation and Mitigation Strategies (REMS) through Systematic Analysis, Standardized Design, and Evidence-Based Assessment. The Engelberg Center for Health Care Reform, Brookings Institution, Washington, DC, September 25, 2013.
- 2013 Invited participant, Expert Workshop on the Safety and Long-Term Efficacy of Extended-Release and Long-Acting Opioid Analgesics, co-hosted by the FDA's Center for Drug Evaluation and Research and the Clinical Trials Transformation Initiative (CTTI), Silver Spring, MD, August 12-13, 2013.
- 2013 Invited contributor, principles for good comparative effectiveness research, as published in: The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution. *Dreyer NA, Velentgas P, Westrich K, Dubois R. J Manag Care Pharm. 2014; 20(3):301-8.*
- 2010-2013 Comparative Effectiveness Research (CER) Key Function Committee, National Center for Research Resources (NCRR) of NIH and the National Clinical and Translational Science Award (CTSA) Consortium
- 2009-2013 Member, FDA Drug Safety and Risk Management Advisory Committee
- 1.
- 2012 Invited participant, Public Workshop on Risk Evaluation and Mitigation Strategy (REMS) Assessments: Social Science Methodologies to Assess Goals Related to Knowledge Public Workshop, Silver Spring, MD, June 7, 2012, Docket No. FDA-2012-N-0408
- 2010-2011 Organizing Committee, Conference on Adipogenic and Metabolic Effects of Antipsychotic Drugs (NIMH/NIDDK R13MH086166)
- 2006-2009 Contributor, American Psychiatric Association (APA) Council on Research Workgroup on Antipsychotics and Metabolic Risk. Newcomer JW, Blonde L, Ader M, Beaser R, Marder S, Nemeroff C.

- 2008 Consultant to the FDA Risk Communication Advisory Committee, “Research Regarding Direct to Consumer Advertising of Prescription Drugs” (May 15-16, 2008)
- 2006-2007 Co-Chair, Policy Advocacy Working Group, Retrospective Database Special Interest Group of the International Society for Pharmacoeconomics and Outcomes Research
- 2005-2006 Member, Policy Advocacy Working Group, Retrospective Database Special Interest Group of the International Society for Pharmacoeconomics and Outcomes Research

UNIVERSITY

- 2016 - Member, Aurora Community Campus Partnership Steering Committee (<http://com-cam.org/>) representing the Colorado School of Public Health, University of Colorado Anschutz Medical Campus
- 2016 - Advisor, National Academy of State Health Policy (NASHP) Learning Collaborative *From Engagement to Evidence: Using PCOR and CER to Inform State Policymaking* in collaboration with the Colorado Department of Public Health and Environment, Office of Behavioral Health, and Health Care Policy & Financing
- 2015 - Member, Colorado Public Health Improvement Steering Committee (PHISC) representing the Colorado School of Public Health, University of Colorado Anschutz Medical Campus
- 2008-2011 Member, Pediatric Scientific and Advisory Review Committee of the Colorado Clinical Translational Research Center (CTRC) of the Colorado Clinical Translational Sciences Institute (CCTSI), University of Colorado Anschutz Medical Campus
- 2009-2010 Member, Sub-committee on Outcomes and Community Research, Development of Children’s Hospital Colorado Strategic Research Plan, School of Medicine, University of Colorado Denver
- 2009 Chair, Faculty Search Committee, Director of the Qualitative Methods Core, Colorado Health Outcomes Program, School of Medicine, University of Colorado Denver

COLORADO SCHOOL OF PUBLIC HEALTH

- 2016 - Department representative, Appointment, Promotion, and Tenure Committee
- 2012, 2015-2016 Member, Departmental Appointments, Promotions, and Tenure Committee (DAPTCO)
- 2015 Member, Faculty Search Committee, Associate Dean for Finance and Administration, Colorado School of Public Health
- 2014 -2015 Department representative, Education and Curriculum Committee
- 2013-2015 Faculty-member-at-large, Executive Council
- 2012-2014 Chair, Faculty Senate Finance Committee
- 2009-2012 Faculty Senate representative, Health Systems, Management and Policy Department
- 2010- Member, Founding Steering Committee for the Doctor of Public Health Program
- 2011-2102 Member, Faculty Search Committee, Associate Professor in Oral Health Epidemiology, Department of Epidemiology
- 2009-2011 Member, Faculty Search Committee, Assistant/Associate Professor in Health Services Research, Department of Health Systems, Management & Policy

2007 Reviewer, Doctorate of Public Health program proposal. Colorado School of Public Health Initiative, University of Colorado at Denver and Health Sciences

OTHER SERVICE RESPONSIBILITIES

2007-2008 Co-chair, Bergen Valley and Bergen Meadow Elementary School Science Fair, Evergreen, CO

2007 Guest Speaker, Topic: How I use statistics in my job. Bergen Valley Elementary School, Evergreen, CO

2005, 2006 Guest Speaker, Food nutrition and how to read and understand food labeling. Bergen Valley Elementary School, Evergreen, CO

2004 Student representative to faculty, Doctorate of Public Health Program Executive Committee, Johns Hopkins Bloomberg School of Public Health

1998-1999 Member, Committee to develop the Pharmaceuticals Division Technical Brand Training Manual on Best Practices. The Procter & Gamble Company.

1992-1995 Qualitative Methods Instructor, corporate training course: "PRISM 101, Understanding consumers and communicating with them", The Procter & Gamble Company

1992, 1994 Instructor, Health Care Division Diversity program, The Procter & Gamble Company.

1986-1988 President, School of Science Student Council, Purdue University

BOARD CERTIFICATION

2008 Board Certification in Public Health (Inaugural Class), National Board of Public Health Examiners (Recertified 2012, 2015)

REVIEW, REFEREE, and EDITORIAL ACTIVITIES

GRANT REVIEW COMMITTEES AND STUDY SECTIONS

2016 Invited reviewer, Mental Health Services Research Committee, National Institute of Mental Health

2016 Invited reviewer, Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (RFA-MH-15-320 and RFA-MH-15-325), National Institute of Mental Health

2015 Invited reviewer, Fellowship and Dissertation Awards, National Institute of Mental Health

2015 Invited reviewer, Mental Health Services Research Committee, National Institute of Mental Health

2014 Special Emphasis Panel, National Institute of Mental Health, ZMH1 ZMH1 ERB-K (04) Mental Health Services

2014 Special Emphasis Panel, National Institute of Mental Health, ZMH1 ZMH1 ERB-K (02) Mental Health Services

- 2014 Invited reviewer, Mental Health Services Research Committee, National Institute of Mental Health
- 2014 Special Emphasis Panel, National Institute of Mental Health, ZMH1 ERB-I (03), Improving Health and Reducing Premature Mortality in People with Severe Mental Illness
- 2013 Cycle III Merit Review, Patient Centered Outcomes Research Institute (PCORI), Communication and Dissemination, July 18-19, 2013, Boston, MA
- 2012 Cycle I Merit Review, Patient Centered Outcomes Research Institute (PCORI), Assessment of Prevention, Diagnosis, and Treatment Options
- 2012 Special Emphasis Panel, Agency for Healthcare Research and Quality, ZHS1 HSR-X 03 1, Dissemination by Health Professionals Associations
- 2009 Special Emphasis Panel, National Institutes of Health, 2009/10 ZRG1 HDM-P(58), Challenge Grants in Health and Science Research

INVITED LECTURES, PRESENTATIONS, WORKSHOPS

INTERNATIONAL

1. Invited speaker, *Pragmatic Trials*, 7th International Congress of the International Dermatoepidemiology Association (IDEA). Aurora, CO. September 28-30, 2016.
2. Workshop Faculty, "Implementation Science: A Pragmatic Approach for Designing Risk Management Programs" in the Pre-Conference *Introduction to Therapeutic Risk Management Education Session* at the 32nd *International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*, Dublin, Ireland, August 25-28, 2016.
3. Invited panel speaker, *Mind the Gaps - and Address Them! The science of designing, implementing and evaluating benefit-risk communication for medicinal products*. Drug Information Association 2016 52nd Annual Meeting, Philadelphia, PA, June 26-30, 2016.
4. Planning Committee and moderator, *Patient Engagement in Benefit-Risk Assessment throughout the Life Cycle of Medical Product*. Sponsored by the Drug Information Association and the Patient-Centered Outcomes Research Institute. Rockville, MD, September 17-18, 2015.

See: <http://www.pcori.org/research-results/2015/patient-engagement-benefit-risk-assessment-throughout-life-cycle-medical>
5. Invited speaker, "Practical Approaches to Designing, Implementing, and Evaluating REMS and Risk Minimization Programs" for Amgen Inc., Thousand Oaks, CA, April 13, 2015
6. Planning Committee, Pre-Conference Educational Session, *A State-of-the-Art Review of Benefit-Risk Assessment and Risk Communication Practice*, Sponsored by the Benefit-Risk Assessment, Communication and Evaluation (BRACE) Special Interest Group. Presenter, "Diffusion of Innovation Theory: Considerations for designing, implementing, and evaluating drug risk communication & management". 29th *International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28, 2013.
7. Symposium moderator, *Benefit-Risk Assessment, Communication and Evaluation (BRACE): Embrace the challenges and opportunities*. Sponsored by the Benefit-Risk Assessment,

Communication and Evaluation (BRACE) Special Interest Group. *29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28, 2013.

8. Invited Speaker, “Methodologic issues in epidemiologic and pharmacovigilance studies of APD metabolic effects”, Conference on *Adipogenic and Metabolic Effects of Antipsychotic Drugs* with funding in part from the National Institute of Mental Health and the National Institute of Diabetes and Digestive and Kidney Disease (R13MH086166), Newark, NJ, July 11-12, 2011.
9. Think Tank leader, **Morrato EH**, Marosits M, Dearing JW. *Social Network Science and Social Media Tools*, 4th Annual National Institutes of Health Conference on the Science of Dissemination and Implementation, Bethesda, MD, March 21-22, 2011.
10. Symposium, Mol P, Bahri P, Avorn J, Benkimoun P, Aria A, **Morrato EH**, DelPan G, Haaijer-Ruskamp F, Straus S. “Intended and Unintended Consequences: The case example of SSRI suicidality risk communication” in “Regulatory Risk Communication: Are We Getting Ahead?” *26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management*, Brighton, UK, August 19-22, 2010.
11. Invited Speaker, “Comparative Effectiveness Research Funding in the United States” *Cochrane Skin Group Annual Meeting*, University of Colorado Denver, Aurora, CO, October 16-17, 2010.

NATIONAL

1. (b) (4)
1. (b) (4)
2. Webinar presentation, “An Introduction to Implementation Science”, Palliative Care Research Cooperative Group Investigator Meeting, Denver, CO, July 13, 2016.
3. Invited speaker, “An Introduction to Implementation Science”, Palliative Care Research Cooperative Group Investigator Meeting, Denver, CO, March 24, 2016.
4. Invited speaker, “Metabolic Screening: Prioritizing Implementation Strategies for Mental Health” (findings from R21 MH 097045). SMINET: Applying Evidence to Improve Care and Outcomes in Severe Mental Illness AHRQ 1R18HS023258, February 22, 2016.
5. Research symposium speaker, “Implementation of Appropriate Use of Clinical Preventive Services: Setting a National Research Agenda” with Therese Miller and Stacey Sheridan. Agency for Healthcare Research and Quality Annual Research Meeting Co-hosted with Academy Health, Arlington, VA. October 5, 2015.
6. Invited workshop, “Introduction to Implementation Science” for the American Academy of Pediatrics, Chicago, IL, April 1, 2015.
7. Invited speaker, “Metabolic Screening: Prioritizing Implementation Strategies for Mental Health Patients”. *Missouri CMHC Healthcare Home Operations Meeting*. August 18, 2014.

8. CME Symposium, Miller T, Harris R, Baker D, and **Morrato EH**. “The Importance of Population Thinking in Prevention” *Preventive Medicine 2014*. New Orleans, LA, February 19-22, 2014.
9. Invited speaker, “Marketing: What Can We Learn to Improve Health Dissemination and Implementation?” University of Washington Centers for Comparative & Health Systems Effectiveness, CHASE Alliance. Seattle, WA, March 11, 2013.
10. Invited keynote speaker, “Metabolic Monitoring among Persons with Mental Illnesses: Lessons Learned, Insights for Future Direction”, *Physical Health and Behavioral Health Integration: Preventing Diabetes among People with Mental Illness*. CME lecture sponsored by APS Healthcare and Maine Department of Health and Human Services Data Forum and the Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes and the Center for Education and Research on Mental Health Therapeutics, Rutgers University. Maine webinar, January 31, 2013.
11. Panel speaker, “Mixed methods in health services research to understand real-world acceptance of safety recommendations for psychopharmacologic treatments” in the presentation on “Balancing Benefits, Risks and Cost for New Treatments in Vulnerable Populations: Lessons from Child Psychiatry on the Need for a New Standard of Diverse Methodologies”. Co-Chairs: Correll C and Newcomer JW. Panelists: Arango C, Nicol G, **Morrato E**, Kymes S. 51st *American College of Neuropsychopharmacology (ACNP) Annual Meeting* in Hollywood, FL, December 2-6, 2012.
12. Invited keynote speaker, “Metabolic Monitoring: Current Knowledge, Future Directions”, *Integrating Behavioral Health and Primary Care: Antipsychotic Medications and Cardiometabolic Monitoring*. CME lecture sponsored by CalOptima, Beacon Health Strategies, Orange County Health Care Agency, and the Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes and the Center for Education and Research on Mental Health Therapeutics, Rutgers University. Orange County, CA, June 13, 2012.
13. Invited panelist, FDA Public Workshop “Risk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Assess Goals Related to Knowledge” June 7, 2012, Silver Spring, MD. June 7, 2012.
14. Invited speaker, “Dissemination and Implementation of CER Evidence: What Can We Learn from the Consumer Products Industry?” DARTNet Comparative Effectiveness Research (CER) Learning Group, May 24, 2012.
15. Invited speaker, “Drug Safety Policy in the U.S.: Current Direction and Public Health Considerations” Mental Health Concentration Seminar, Rollins School of Public Health, Emory University, January 25, 2012.
16. Work Group presentation, **Morrato EH**, Meissner P, Concannon TW, Tobin J, Shah N. “Key Informant Interviews: CER Dissemination and Implementation among CTSA Institutions (preliminary findings)”. CER Collaboration, Information Dissemination, Implementation Work Group, Presented at the Annual Comparative Effectiveness Research Key Function Committee Meeting, October 11, 2011. Rockville, MD.
17. Invited speaker, **Morrato EH**, “Diffusion of Drug Warnings Among Physicians: Getting the most out of electronic patient data” U.S. Food and Drug Administration Center for Drug Evaluation

and Research (CDER), Office of Surveillance and Epidemiology Seminar Series, Silver Spring, MD, June 23, 2011.

18. Panel discussant, Eggleston M, Frasso R, Harris HS, Masterson EA, **Morrato EH**, Navarro Silvera S. "Everything you ever wanted to know about being Certified in Public Health, but didn't know who to ask" *138th American Public Health Association Annual Meeting*, Denver, CO November 6-10, 2010.
19. Plenary Panel, **Morrato EH**, "Synthesis, generation and translation of comparative effectiveness evidence and patient-centered outcomes research" in "Health Care Reform: How will we measure progress?" *The Culture of Data 2010: Health Reform and Health Disparities: Where from here?*, U.S. Department of Health and Human Services U.S. Public Health Service Region VIII, The Arvada Center for the Performing Arts, Arvada, CO, October 8, 2010.
20. Invited Speaker, **Morrato EH**, "Diffusion of Drug Warnings The Case Example of Antipsychotics and Metabolic Risk", Rocky Mountain Poison Control and Drug Center, Denver Health Association, Denver, CO, September 2, 2010.
21. Symposium presenter, Newcomer JW, Haupt D, **Morrato EH**, Parks J. "Why psychiatry is a branch of medicine: an update on screening and monitoring cardiometabolic risk during mental health treatment." *60th Institute on Psychiatric Services*. Chicago, IL, October 2-5, 2008.
22. Visiting Professor, **Morrato EH**, "Atypical antipsychotic drugs and metabolic testing: Assessing response to the FDA warnings", U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Visiting Professor Lecture Series (VPLS), Rockville, MD, July 2008.
23. On-line CME poster presenter, **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Impact of the atypical antipsychotic FDA Warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. NCDEU CME Poster Session 2008. Best research posters presented at the 2008 NCDEU (New Clinical Drug Evaluation Unit) Meeting. CME Institute, Physicians Postgraduate Press, Inc., *The Journal of Clinical Psychiatry*, October 2008.
24. On-line CME lecturer, **Morrato EH**, "Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population based study of Medicaid claims data", Schizophrenia CME E-Journal Club, Editor: John M. Kane, Albert Einstein College of Medicine, May 2008.
25. On-line CME lecturer, **Morrato EH**, "Physical Activity in U.S. Adults with Diabetes and At Risk For Developing Diabetes", Primary Care Edition of the Cardiometabolic E-Journal Club, Editor: Jorge Plutzky, Brigham and Women's Hospital, Harvard Medical School, January 2008.
26. Invited presenter, **Morrato EH**, "Drug safety: Can it be managed?" Graduate Summer Institute of Epidemiology and Biostatistics Seminar Series, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, June 2007.
27. Invited presenter, **Morrato EH**, "Epidemiology of pediatric surgery" Pediatric National Surgical Quality Improvement Program (NSQIP): protocol development meeting, American College of Surgeons, Chicago, IL, April 2007.
28. Invited presenter, "Impact of Nefazodone (Serzone®) Hepatic Risk Minimization Recommendations: A Case Study Evaluation of an FDA Boxed Warning", Office of Drug Safety Research Seminar, U.S. Food and Drug Administration, Rockville, MD, June 2006.

29. “Utilization of Retrospective Databases to Inform Evidence Based Drug Policy Making” International Society for Pharmacoeconomics and Outcomes Research 11th Annual International Meeting. Philadelphia, PA, May 2006.
30. “Ethical Issues in Drug Product Risk Assessment and Communication” Western Drug Safety and Pharmacoepidemiology Conference. Napa, CA, October 2005.
31. “Impact of Relabeling on Nefazodone (Serzone®) Prescribing: A Risk Minimization Evaluation”, First Western Pharmacoeconomics Conference. Salt Lake City, UT, March 2005.
32. “HELIDAC Therapy: A Newly FDA-Cleared Therapy Designed for Compliance,” International Business Communications Meeting on *H. pylori*, January 1997.

LOCAL - COLORADO

1. (b) (4)
2. Invited Speaker, “FDA, Prescription Drugs and You”, Tuesday Morning Class Denver, Colorado (December 2015)
3. Invited Speaker, “Pulling Back the Curtain: the FDA, Prescription Drugs, and You”, The University of Colorado Boulder Directors Club, Vail, Colorado (June 2015)
4. Invited Speaker, “Dissemination and Implementation Science: Resources and Opportunities”, Department of Medicine Faculty Conference Research and Innovation, University of Colorado Anschutz Medical Campus (January 2014)
5. Rabin B, **Morrato EH**. “Dissemination and Implementation Science and Practice 101” Skill-Building Session, Public Health in the Rockies Conference, Breckenridge, CO (September 2013)
6. Speaker, “The Field of Healthcare Marketing: Implications for Dissemination and Implementation Practice”, Insights and Innovation in Improving Health Seminar Series, Center for Research in Implementation Science and Prevention (CRISP), University of Colorado, Anschutz Medical Campus (January 2013)
7. Invited panelist, “Dissemination and Implementation”, Qualitative Methods Showcase, University of Colorado, Anschutz Medical Campus (October 2012)
8. Speaker, “Questions concerning periodontal disease prevalence in adolescents with diabetes: clinical and health education implications”, Colorado Health Outcomes Research Seminar, University of Colorado Denver, Aurora, CO (November 2010)
9. Speaker, “Caregivers’ and Relatives’ Expectations for Spinal Surgery (CARES) Study” with Juli Barnard, Colorado Health Outcomes Research Seminar, University of Colorado Denver, Aurora, CO (February 2009).
10. Speaker, “Influences of Individual and Geographic Factors on Drug Safety Practices: Applications for Antipsychotics and Diabetes Risk”, Colorado Health Outcomes Methods and Applications Seminar, University of Colorado Denver, Aurora, CO (January 2009).

11. Speaker, “Epidemiology of Pediatric Surgery: Results from KID 2003” with Katie Benton, Colorado Health Outcomes Research Seminar, University of Colorado Denver, Aurora, CO (April 2008)
12. Speaker, “Understanding Quality of Life issues for children undergoing spinal fusion surgery for scoliosis: the special case of children with neuromuscular disorders”, Qualitative Methods Research Forum, University of Colorado Denver, Denver, CO (November 2007)
13. Speaker, “*PHIS and KID*: Secondary data sources for pediatric hospitalization outcomes”, Colorado Health Outcomes Research Seminar, University of Colorado at Denver and Health Sciences Center, Aurora, CO (April 2007)
14. Speaker, “Specificity and sensitivity: Implications for clinical decision making and research” Rehab Science and Engineering Consortium (RSEC) Seminar, University of Colorado at Denver and Health Sciences Center, Denver, CO (April 2007)
15. Speaker, “Evaluating Physician Adoption of FDA Drug Warnings: How do we get the most out of administrative claims data?” Department of Preventive Medicine Research Seminar, University of Colorado at Denver and Health Sciences Center, Denver, CO (January 2007)
16. Speaker, “Lessons Learned from Consumer Product Research” Qualitative Research Methods Forum, University of Colorado at Denver and Health Sciences Center, Aurora, CO (November 2006)
17. Speaker, “From MEPS to Medicaid: Outcomes Research Learning in Diabetes and Mental Health” Fellowship Seminar, Department of Clinical Pharmacy Seminar Series, University of Colorado at Denver and Health Sciences Center, Denver, CO (July 2006)
18. Speaker, “Pharmaceutical Risk Management Evaluation”, Colorado Health Outcomes Methods and Applications Seminar, University of Colorado at Denver and Health Sciences Center, Aurora, CO (February 2006)

TEACHING RECORD

AWARDS AND RECOGNITION

- | | |
|------|---|
| 2013 | Training the Next Generation of Leaders in Clinical Preventive Services: Profiles from the AHRQ Research Centers for Excellence. November 2013. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/professionals/prevention-chronic-care/decision/research-centers/rce_profile_morrato.html

Also see: Achievements in Prevention: Training to Implement Clinical Preventive Services at http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/prevention-chronic-care/decision/research-centers/training_professionals.pdf |
| 2013 | “Science Meets Writing: Health science instructors utilize Writing Center to develop student skills” by Amy Vaerewyck. <i>Spotlight Stories</i> . University of Colorado Denver Anschutz Medical Campus. October 14, 2013. http://www.ucdenver.edu/about/newsroom/spotlight/students/Pages/Public-Health-Writing.aspx |
| 2012 | President’s Excellence in Teaching Award, Colorado School of Public Health, University of Colorado |

NATIONAL CURRICULA DEVELOPMENT AND EDUCATION

- 2014 Conference for Developing Curricula for Teaching Patient Centered Comparative Effectiveness Research sponsored by the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, Pew Charitable Trust, and the PhRMA Foundation, Washington, D.C., January 28-29, 2014.
- 2013 Item Writer, Epidemiology and Health Policy & Management, for Board Certification in Public Health, National Board of Public Health Examiners
- 2011 Invited book chapter, annotated bibliography, and self-assessment questions on “Pharmacovigilance and FDA Drug Safety Policy”, Chronic Illnesses, Pharmacotherapy Self-Assessment Program, Seventh Edition, for Board Certification in Clinical Pharmacy, American College of Clinical Pharmacy

GRADUATE PROGRAM CURRICULUM DEVELOPMENT (University of Colorado Anschutz Medical Campus)

- 2014-2015 Program Director, Certificate of Professional Achievement in Health Industry Analytics Pilot Program, Colorado School of Public Health, CU South Denver
- 2009-2010 Co-Developer (representing the Department of Health Systems, Management, and Policy), Doctor of Public Health Program, Colorado School of Public Health

COURSES TAUGHT AND DEVELOPED (University of Colorado, Anschutz Medical Campus)

- 2015, 2016 Director and Course Developer: Introduction to Health Systems, Management and Policy (HSMP 6601). Colorado School of Public Health.
- 2015, 2016 Invited Lecturer: Clinical Reasoning and Decision Making (PRDO 7800, iPharmD[®] program). Topic: Clinical Decision Making Process: Government, Law, Industry. Skaggs School of Pharmacy and Pharmaceutical Sciences
- 2014-2016 Invited Lecturer: Clinical Reasoning and Decision Making (PHRD 6965). Topic: Decision Making: Drug Warnings. Skaggs School of Pharmacy and Pharmaceutical Sciences
- 2014, 2016 Invited Lecture: Dissemination and Implementation Research in Health (CLSC 7653). Topics: The Field of Healthcare Marketing: Implications for Dissemination and Implementation Practice and Health Policy Implementation. Clinical Science Graduate Program
- 2015 Director and Course Developer: Quality Improvement (HSMP 6643)
- 2015 Invited Lecturer: Evidence Based Medicine (MPAS 6701) Topic: comparative effectiveness research. Child Health Associate / Physician Assistant Program. School of Medicine.
- 2015, 2011 Invited Lecturer: Pharmacoepidemiology (PHSC 7615 / EPID 7615) Topics: (1) The FDA Drug Approval Process, (2) Pharmaceutical Risk Management Practices, and (3) Pharmaceutical Risk Communication to Health Providers and Patients. School of Pharmacy and Colorado School of Public Health
- 2011-2014 Sole Instructor and Course Developer: Health Policy (HSMP 6605). Colorado School of Public Health
- 2013 - 2014 Course Developer. Introduction to Health Policy Analysis and Communication (HSMP 6616). Colorado School of Public Health

- 2012 - 2013 Invited Lecturer: GIS Application in Health Policy. GIS for Public Health Research and Practice (EHOH 6621). Colorado School of Public Health
- 2012 Invited Lecturer: Research Methods using Secondary Datasets (EPID 7605). Topic: Secondary Datasets Used in Health Services Research. Colorado School of Public Health
- 2011 Co-Instructor: GIS for Public Health Research and Practice (EHOH 6621). Colorado School of Public Health
- 2011 Invited Lecturer: Transition to Residency and Beyond (ICC 8004). Topic: FDA Drug Regulation. School of Medicine
- 2011, 2009 Invited Lecturer: Pharmacoepidemiology (PHSC 7615 / EPID 7615) Topics: (1) The FDA Drug Approval Process, (2) Pharmaceutical Risk Management Practices, and (3) Pharmaceutical Risk Communication to Health Providers and Patients. School of Pharmacy and Colorado School of Public Health
- 2010, 2011 Invited Lecturer: Health Services Research in Public Health and Health Policy Research (HSMP 6670). Topic: Comparative Effectiveness Research in the U.S. Colorado School of Public Health
- 2009 Invited Lecturer: Applied Database Research (PHSC 7622). Topic: Analyzing Medicaid Data. School of Pharmacy
- 2008 Invited Lecturer: Special Topics in Outcomes Research (PHSC 7570). Topic: FDA, Risk Evaluation and Mitigation Strategies (REMS), and Future Direction for Drug Safety Policy. School of Pharmacy
- 2008 Invited Lecturer: Database Research Methods (PHSC 7621). Topic: Medicaid Databases. School of Pharmacy
- 2007 Invited Lecturer: Biostatistics (PHRD 4400). Topic: Study Designs in Clinical Research. School of Pharmacy
- 2006-2008 Invited Lecturer: Cost Effectiveness Analysis and Pharmacoeconomics (PHRD 5400). Topic: U.S. Drug Advertising and Patient-Reported Outcomes. School of Pharmacy
- 2005-2008 Invited Lecturer: Health Care Systems (PRMD/HSMP 6603). Topic: Drug Development and the History of FDA Regulation. School of Medicine
- 2005, 2006 Invited Lecturer: Biostatistics (PHRD 4400). Topic: Categorical Data: Comparing Groups. School of Pharmacy
- 2005 Invited Lecturer: Biostatistics (PHRD 4400). Topic: Descriptive Statistics. School of Pharmacy
- 2004 Invited Lecturer: Biostatistics (PHRD 4400). Topic: Hypothesis Testing and Power. School of Pharmacy

COURSES TAUGHT AND DEVELOPED (Johns Hopkins Bloomberg School of Public Health)

- 2007 Invited Lecturer: Pharmacoepidemiology (340.617.11). Topic: Drug Safety and Risk Management. Epidemiology and Biostatistics Summer Institute
- 2003 Teaching Assistant: Data Analysis Workshops I and II (140.613 and 140.614). Winter Institute

WORKSHOPS DIRECTED

- 2013 “Introduction to Dissemination and Implementation Science Workshop”, Center for Research in Implementation Science and Prevention, University of Colorado Anschutz Medical Campus, Aurora, CO

2015 “Introduction to Pragmatic Trials”, Center for Research in Implementation Science and Prevention, University of Colorado Anschutz Medical Campus, Aurora, CO

LECTURE SERIES DIRECTED AND DEVELOPED (University of Colorado Anschutz Medical Campus)

2013-2015 Founded and directed, Colorado Research on Implementation Science Program (CRISP) seminar series

2006-2007 Outcomes Research Methodology Series for the Department of Pediatric Surgery, Children’s Hospital Colorado, Aurora, CO

RESEARCH RECORD

ACADEMIC: ACTIVE

PRINCIPAL INVESTIGATOR

Implementation Research Agenda: Appropriate Use of Clinical Preventive Services

R13 HS23723-01, AHRQ (PI: Morrato) 11/2014–11/2016

Purpose: This conference will develop a national implementation science research agenda to address issues of under-, over- and inequitable use of clinical preventive services in primary care.

Role: Principal Investigator

Amount: \$33,000 (direct costs)

SITE PI OR LEADER OF A CORE

Colorado Clinical and Translational Sciences Institute (CCTSI)

UL1TR001082, TL1TR001081, KL2TR001080, NIH / NCATS (PI: Sokol) 10/2013 – 9/2018

Purpose: The Clinical and Translational Science Award (3 grants) to the University of Colorado Denver will support the institutional academic home for research and training in clinical and translational sciences. This award is for continuation of the CCTSI during 2013-2018.

Roles: Director, Pragmatic Trials and Dissemination/Implementation Core Unit
Director, Innovation-Corps@CCTSI

(b) (4)



(b) (4)



(b) (4)

CO-INVESTIGATOR

**Problem-Solving Skills Training for Clinicians
Providing Psychosocial Care in Pediatric Oncology**

04/15/2015-03/31/2020

R25 CA183725, NCI/NIH (Co-PIs: Sahler, Noll)

Purpose: Research aims to identify specific coping strategies that would facilitate the adjustment of caregivers learning their child had been diagnosed with cancer.

Role: Co-Investigator

Maximizing Care Management Effectiveness in Primary Care

08/01/14-01/31/17

1R18HS022690-01, AHRQ (PI: Holtrup)

Purpose: Research has shown that care management services can improve chronic disease patient outcomes, however, in real-world implementation, results are mixed. This study will add to the field by providing practical and translatable information about what makes care management work and *how quality improvement activities may be related to care management improvement over time* as to maximize the benefit of this new service in community-based primary care.

Role: Co-Investigator, Social Network Analysis

**Pediatric Obesity and Type 2 Diabetes (T2D)
in American Indian Youth (PI: Sauder)**

8/1/2015-7/30/2016

Pilot award from the Center for American Indian and Alaska Native Diabetes Translational Research
P30DK092923, NIDDK/NIH (PI: Manson)

Purpose: To investigate sustainable implementation of a pediatric nutrition program within the larger Navajo Nation community and plan for a larger dissemination and implementation research study that will expand the program to additional AI communities.

Role: Co-Investigator

Methods Training in Patient-Centered Cancer Outcomes Research

6/1/1014 – 5/31/2019

1 R25 HS 023214-01, AHRQ (PI: Suarez-Almazor)

Purpose: The overall goal of this training program is to increase the nation's workforce for conducting cancer-related comparative effectiveness research and patient-centered outcomes research through an innovative, accessible curriculum tailored to the needs and skills of the participants.

Role: Scientific Advisory Committee

Building Networks of Engaged Parents for Patient-Centered Pediatric Research 4/1/2015-3/31/2017
Contract 1300-UCD, PCORI (PI: O’Leary)

Purpose: The project objective will be to develop a replicable model for engaging patients, parents, clinicians, and other stakeholders in the collaborative development of research questions and patient-centered research relevant to child health in the PBRN setting.

Role: Leadership Advisory Board

ACADEMIC: COMPLETED

PRINCIPAL INVESTIGATOR

Metabolic Screening: Prioritizing Implementation Strategies for Mental Health 12/2012 – 12/2015
R21 MH 097045, NIMH (PI: Morrato)

Purpose: To determine the relative importance of provider and practice factors on diabetes and dyslipidemia screening in persons with mental illness in order to identify and prioritize intervention target groups for screening implementation interventions

Role: Principal Investigator

Colorado CER and Safety Scholars Program: Mental Health, CVD, and Methods 7/2010 – 6/2013
K12 HS019464, AHRQ (PI: Libby)

Purpose: To develop a new K12 program in Comparative Effectiveness Research (CER) and Safety education and address career development needs and mentorship capacity as part of a longitudinal infrastructure to improve the CER workforce and leadership pools of the future. My project is entitled “*Accelerating the Diffusion of CER Evidence into Clinical Practice*”.

Role: CER K12 Scholar

(b) (4)



Periodontal health in adolescents with Type 1 Diabetes Mellitus 9/2006 – 9/2010
MO1-RR00069, NCRR, NIH
Delta Dental Frontier Center
Procter & Gamble (unrestricted gift for oral health and diabetes research)

Purpose: To investigate the prevalence of periodontal disease in adolescents with Type 1 diabetes in relationship to oral health knowledge and self-hygiene behaviors and diabetes control

Role: Principal Investigator

SITE PI OR LEADER OF A CORE

Center for Research in Implementation Science and Prevention (CRISP) 10/2011 – 9/2015
1 P01 HS021138-01, AHRQ (PI: Kempe)

Purpose: This project brought together local and national experts in primary care and public health delivery to conduct research on ways to increase use of preventive health services within primary care settings. The Center will develop “toolkits” and publish articles to guide researchers in how to improve delivery of preventive health care.

Role: Collaborative Scientific Lead and Director, Training and Education

SAFTINet: Optimizing Value and Achieving Sustainability 09/30/2013 – 03/31/2015
R01 HS022956, AHRQ (PI: Schilling)

Purpose: To enhance the capabilities of an existing data network, the Scalable Architecture for Federated Translational Inquiries Network (SAFTINet), by improving its ability to conduct comparative effectiveness research, with special emphasis on the poor and disadvantaged; and by planning for its financial sustainability.

Role: Co-Investigator, Sustainability plan development

Scalable Architecture for Federated Therapeutic Inquiries Network (SAFTINet). 10/2010 – 9/2013
Agency for Healthcare Research and Quality (R01 HS019908-01) (PI: Lisa Schilling)

Purpose: This multi-state registry development project will allow researchers, health policy experts, payers, and clinicians to investigate the impact of a wide variety of health care interventions on health outcomes for minority, underserved and socioeconomically disadvantage populations.

Role: Consultant

SocioWorks: Integrated web-platform for applications of social network analysis 9/2010 – 8/2013
R44 AG038316, National Institute on Aging, NIH (PI: Allen Tien, mdlogix, inc.)

Purpose: To create a technologically and organizationally scalable web application toolset for social network methods and their application to improving health and productivity.

Role: Co-Investigator and Demonstration Project Leader for Policy Application

Children’s Outcomes Research (COR) Program 1/2007 – 5/2015
The Children’s Hospital Research Institute (PI: Kempe)

Purpose: To improve pediatric health outcomes and reduce health disparities, with a focus on immunization delivery, comparative effectiveness research, pediatric surgical outcomes, oral health disparities, obesity prevention, and asthma and emergency medicine.

Role: Associate Director of the Program (2009-2013), Director the Comparative Effectiveness Research Core (2010-2013), Investigator (2013-2105)

(b) (4)



Center for Native Oral Health Research (CNOHR).

6/2008 – 5/2015

U54 DE019259-02, National Institute of Dental and Craniofacial Research, NIH (PI: Judith Albino)

Purpose: To reduce oral health disparities in American Indians and Alaskan Natives through community-based interventions

Role: Co-Investigator, 2008-2009

(b) (4)



(b) (4)



CO-INVESTIGATOR

Pediatric National Surgical Quality Improvement Program

9/2006 – 8/2009

American College of Surgeons (Site PI: William Henderson)

Purpose: To provide statistical and epidemiological guidance on protocol development and pilot-testing of the Pediatric National Surgical Quality Improvement Program (Pediatric NSQIP)

Role: Co-Investigator on the Statistical Core

(b) (4)



(b) (4)



PRIVATE SECTOR: COMPLETED (PROCTER & GAMBLE)

(b) (4)



(b) (4)



(b) (4)



BIBLIOGRAPHY

PEER-REVIEWED JOURNAL ARTICLES

‡ *Senior author*

(b) (4)

ase or editorial from the journal or received notice

from a secondary medical news outlet.

1. Sullivan PW, **Morrato EH**, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. *Diabetes Care*. 2005; 28(7): 1599-1603.
2. **Morrato EH**, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Are health care professionals advising patients with diabetes or at-risk for developing diabetes to exercise more? *Diabetes Care*. 2006 Mar; 29(3):543-8.
3. McCollum M, Ellis SL, **Morrato EH**, Sullivan PW. Prevalence of multiple cardiovascular risk factors in U.S. adults with diabetes. *Current Medical Research and Opinion*. 2006; 22(4): 1031-1034.
4. **Morrato EH**, Staffa JA. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. *Pharmacoepidemiology and Drug Safety*. 2007 16(1):104-12.; doi 10.1002/pds.1279.
5. **Morrato EH**, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns and predictors of antipsychotic polypharmacy: experience from a Multi-State Medicaid Population (1998-2003). *Clinical Therapeutics*. 2007. Jan;29(1):183-95.
6. ***Morrato EH**, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults with diabetes and at-risk for developing diabetes, 2003. *Diabetes Care*. 2007 Feb;30(2):203-9.
7. *Libby AM, Brent DJ, **Morrato EH**, Orton HD, Allen R, Valuck RJ. Pediatric depression treatment declines after FDA advisory on suicidality risk of SSRI antidepressants. *Am J Psychiatry*. 2007; 164: 884-891.
8. Valuck RJ, Libby AM, Orton HD, **Morrato EH**, Allen RR, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA Advisory on risk of pediatric suicidality with SSRIs. *Am J Psychiatry*. 2007 Aug; 164(8):1198-1205.
9. Valuck RJ, **Morrato EH**, Dodd S, Oderda G, Haxby DG, Allen RR. How expensive is antipsychotic polypharmacy? Experience from five state Medicaid programs. *Current Medical Research and Opinion*. 2007; 23(10): 2567-2576.
10. **Morrato EH**, Elias M, Gericke, C. Population-based data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK, and USA. *Journal of Public Health*. 2007; doi:10.1093/pubmed/fdm065.
11. ***Morrato EH**, Libby AM, Orton HD, deGruy III, FV, Brent DA, Allen RR, Valuck RJ. Frequency of provider contact after FDA warning on suicidal risk of antidepressants in children. *Am J Psychiatry*. 2007; 10.1176/appi.ajp.2007.07010205.

12. **Morrato EH**, Curbow B, Crum R, Nowels C, Feinleib, M. Communicating drug risk to physicians: challenges and opportunities. *International J of Risk & Safety in Medicine* 2008; 20(3): 143-154.
13. **Morrato EH**, Dillon P, Ziegler MM. Surgical outcomes research: A progression from performance audits, to assessment of administrative databases, to prospective risk-adjusted analysis. How far have we come? *Curr Opin Pediatr* June 1, 2008; 20(3): 320-325.
14. Dillon P, Hammermeister K, **Morrato EH**, Kempe A, Oldham K, Moss L, Marchildon M, Ziegler M, Steeger J, Rowell K, Shiloach M, Henderson W. Developing a NSQIP module to measure outcomes in children's surgical care: opportunity and challenge *Semin in Pediatr Surg* May 1, 2008; 17(2): 131-140.
15. **Morrato EH**, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population based study of Medicaid claims data. *J Clin Psychiatry*. 2008; 69(2):316-22.
16. **Morrato EH**, Cuffel B, Newcomer JW, Lombard I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. *Journal of Clinical Psychopharmacology*; 2009; 29(1): 26-32.
17. **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the ADA's Statement on antipsychotic drugs and diabetes *Diabetes Care* 2009; 32(6): 1037-1042.
18. Banta JE, **Morrato EH**, Lee SW, Haviland MG. Retrospective Analysis of Diabetes Care in California Medicaid Patients with Mental Illness *Journal of General Internal Medicine*. Jul;24(7):802-8. Epub 2009 May 5.
19. ***Morrato EH**, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Arch Gen Psych* 2010; 67(1): 17-24.
20. ***Morrato EH**, Nicol G, Maahs D, Druss B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic risk monitoring in children receiving second-generation antipsychotic drugs *Arch Ped and Adolesc Med*, 2010 Apr;164(4):344-51.
21. † Orlando VA, Johnson LR, Wilson AR, Maahs DM, Wadwa RP, Bishop FK, Dong F, **Morrato EH**. Oral Health Knowledge and Behaviors among Adolescents with Type 1 Diabetes. *Int J Dentistry*, 2010; 2010:942124. Epub 2010 May 13.
22. **Morrato EH**, Druss B, Hartung DM, Valuck RJ, Thomas D, Allen RR, Campagna E, Newcomer JW. Small Area Variation in Metabolic Risk Management for Patients Initiating Second-Generation Antipsychotics. *Pharmacoepidemiology and Drug Safety* 2010; 20:66-75. 2010 Nov 15.
23. § Nicol GE, **Morrato EH**, Johnson MC, Campagna E, Yingling MD, Pham V, Newcomer JW. *Best Practices: Implementation of a Glucose Screening Program Based on Diffusion of Innovation Theory Methods*. *Psychiatr Serv*. January 2011; 62(1):12-14.
24. *Merchant AT, Jethwani M, Choi Y-H, **Morrato EH**, Liese AD, Mayer-Davis E. Associations between periodontal disease and selected risk factors of early complications among youth with

type 1 and type 2 diabetes: a pilot study. *Pediatric Diabetes* 2011; doi: 10.1111/j.1399-5448.2010.00736.x

25. § Fox D, **Morrato EH**, Campagna E, Rees D, Dickinson LM, Partrick D, Kempe A. Outcomes of Laparoscopic Versus Open Fundoplication in Children's Hospitals: 2005-2008. *Pediatrics* 2011; 127:872-880; doi: 10.1542/peds.2010-1198.
26. Druss BG, Zhao L, Von Esenwein S, **Morrato EH**, Marcus SC. Understanding Excess Mortality in Persons With Mental Illness: 17-Year Follow Up of a Nationally Representative US Survey. *Medical Care* 2011 Jun; 49(6):599-604.
27. Merchant AT, Jethwani M, Choi Y-H, **Morrato EH**, Liese AD, Mayer-Davis E. Oral care practices and A1C among youth with type 1 and type 2 diabetes. *J Periodontology* 2011 Dec 5 [Epub ahead of print]
28. § Sømme S, Bronsert M, Kempe A, **Morrato EH**, Ziegler M. Alignment of the Training Curriculum and Surgical Practice: Implications for Competency, Manpower, and Practice Modeling. *Eur Journal of Pediatric Surgery* 2012 Feb; 22(1): 74-9 Epub 2012 Mar 20.
29. *Concannon TW, Meissner P, Grunbaum JA, McElwee N, Guise J-M, Santa J, Conway PH, Daudelin D, **Morrato EH**, Leslie, LK. A New Taxonomy for Stakeholder Engagement in Patient-Centered Outcomes Research. *Journal of General Internal Medicine*. EPub 2012 Apr 13. DOI: 10.1007/s11606-012-2037-1.
30. Gohlke JM, Dhurandhar EJ, Correll CU, **Morrato EH**, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Adipogenic and Metabolic Effects of APDS Conference Speakers, Allison DB. *Frontiers in Psychiatry* 2012;3:62. Epub 2012 Jun 28.
31. **Morrato EH**, Allison DB, FDA Approval of Obesity Drugs-- A Difference in Risk-Benefit Perceptions. *JAMA* 2012; online Sep 19; 308(11): 1097-1098.
32. § **Morrato EH**, Ling S. The FDA Drug Safety and Risk Management Advisory Committee: A Case Study Evaluation of Meeting Frequency, Content and Outcomes Before and After FDAAA. *Medical Care* 2012; 50 (11): 970-986.
33. †* Victoroff MS, Drury B, Campagna ES, **Morrato EH**. Impact of Electronic Health Records on Malpractice Claims in a Sample of Physician Offices in Colorado: A Retrospective Cohort Study. *Journal of General Internal Medicine* 2012 doi: 10.1007/s11606-012-2283-2.
34. **Morrato EH**. An update on lipid profile screening in second generation antipsychotic users in the United States *Clinical Lipidology* 2012; 7(5): 509-523.
35. Erickson MA, **Morrato EH**, Campagna E, Benefield E, Miller NH, Kempe A. Variability in Spinal Surgery Outcomes among Children's Hospitals in the US. *J Pediatr Orthop* 2013;33:80-90.
36. **Morrato EH**, Concannon TW, Meissner P, Shah ND, Turner BJ. Dissemination and Implementation of Comparative Effectiveness Evidence: Key Informant Interviews with Clinical and Translational Science Award Institutions. *J Comparative Effectiveness Research* 2013; 2(2): 185-194, DOI 10.2217/ce.13.10.
37. Barnard J, Albright K, **Morrato EH**, Nowles CT, Benefield EM, Hadley-Miller NA, Kempe A, Erickson MA. Pediatric Spinal Fusion Surgery and the Transition to Home-Based Care: Provider Expectations and Caregiver Experiences *Health & Social Care in the Community*. 2013 Nov;21(6):634-43. doi: 10.1111/hsc.12049. Epub 2013 May 6.

38. *§ Sømme S, Bronsert M, **Morrato EH**, Ziegler, MM. Frequency and Variety of Inpatient Pediatric Surgical Procedures in the United States. *Pediatrics* 2013 Dec;132(6):e1466-72. doi: 10.1542/peds.2013-1243. Epub 2013 Nov 25.
39. † Campagna E, Muser E, Parks J, **Morrato EH**. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. *J Manag Care Pharm* 2014. Jul;20(7):756-66.
40. † Smith MY, **Morrato EH**. Advancing the field of pharmaceutical risk minimisation through application of implementation science best practices *Drug Safety* 2014 Jul 9. [Epub ahead of print]
41. † Root ED, Thomas DSK, Campagna EJ, **Morrato EH**. Adjusting for Geographic Variation in Observational Comparative Effectiveness Studies: A Case Study of Antipsychotics Using State Medicaid Data *BMC Health Serv Res* [2014] *BMC Health Services Research*.2014, 14:355 DOI: 10.1186/1472-6963-14-355.
42. **Morrato EH**, Parks J, Campagna EJ, Muser E, Thomas DS, Fang H, Doshi D. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. *J Comparative Effectiveness Research* 2014. Sep 24:1-11. [Epub ahead of print]
43. **Morrato EH**, Smith MY. Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved. *Ther Clin Risk Manag* 2015 Feb 26;11:339-48. doi: 10.2147/TCRM.S78202.
44. †§ Nicol GN, Campagna EC, Garfield L, Parks JJ, Newcomer JN, **Morrato EH**. Clinical Setting and Management Approach Matters: Metabolic Testing Rates in Antipsychotic-Treated Youth and Adults *Psych Serv* 2015 1:appips201400428. [Epub ahead of print].
45. **Morrato EH**, Rabin B, Proctor J, Cicutto LC, Battaglia CT, Lambert-Kerzner A, Leeman-Castillo B, Prahl-Wretling M, Nuechterlein BM, Glasgow RE, Kempe A. Bringing it Home: Expanding the Local Reach of Dissemination and Implementation Training via a University-Based Training Workshop 2015 *Implement Sci* 2015 Jul 4;10:94. doi: 10.1186/s13012-015-0281-6.
46. Radawski C, **Morrato EH**, Hornbuckle K, Bahri P, Smith MY, Juhaeri J, Mol P, Levitan B, Huang H-Y, Coplan P, Li J on behalf of the BRACE Special Interest Group. Benefit-Risk Assessment, Communication and Evaluation (BRACE) throughout the Life Cycle of Therapeutic Products: Overall Perspective and Role of the Pharmacoepidemiologist *Pharmacoepidem* Oct 12. doi: 10.1002/pds.3859. [Epub ahead of print]
47. † Merchant, AT, Nahhas GJ, Wadwa RP, Zhang, J, Tang Y, Johnson LR, Maahs DM, Bishop F, Teles R, **Morrato EH**. Periodontal microorganisms and cardiovascular risk markers in youth with type 1 diabetes and no diabetes *J Periodontology* Apr;87(4):376-84. doi: 10.1902/jop.2015.150531. Epub 2015 Nov 28.
48. **Morrato EH**, Brewer, S, Campagna EJ, Dickinson, LM, Thomas, DSK, Druss BG, Miller B, Newcomer JW, Lindrooth RC. Glucose Testing for Adults Receiving Antipsychotics: A Population-Based Prescriber Survey on Behaviors, Attitudes and Barriers in Medicaid *Psych Serv* 2016 Apr 1:appips201500181. [Epub ahead of print]
49. **Morrato EH**, Campagna EJ, Brewer SE, Dickinson LM, Thomas DSK, Miller BF, Dearing J, Druss BG, Lindrooth RC. Metabolic Testing for Adults in a State Medicaid Program taking Antipsychotics: Remaining Barriers to achieving Population Health Prevention Goals. *JAMA Psych* 2016 May 11. doi: 10.1001/jamapsychiatry.2016.0538. [Epub ahead of print]

50. (b) (4)

EDITORIALS AND COMMENTARIES

1. **Morrato EH** Capsule Commentary on Sabbatini et al., Controlling Health Costs: Physician Responses to Patient Expectations for Medical Care. *J Gen Intern Med.* 2014 Sep;29(9):1272. doi: 10.1007/s11606-014-2929-3
2. Interview, Experts call for improved FDA Risk Evaluation and Mitigation Strategy Program. *Endocrine Today.* January 2014.
3. **Morrato EH**, Perspective appearing August 28, 2012 in *Psychiatric Annals* on “Obesity phenotypes in midlife and cognition in early old age, The Whitehall II cohort study” by Singh-Manoux A, et al., *Neurology*, 2012; 79:755-762.
4. **Morrato EH**, Hartung DM, Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice. *Clin Lipidol* 2010;5:299-303

INVITED BOOK CHAPTERS

1. **Morrato EH**, “Comparative Effectiveness and Health Care Reform, Counterpoint Commentary: Patient-Centered Outcomes Research: Putting the patient at the center of comparative effectiveness research” in Debates on U.S. Health Care Reform. Kronenfeld J, Parmet W, Zezza M, eds. Thousand Oaks, CA: SAGE, 2012. ISBN: 9781412996020.
2. **Morrato EH**, “Social Science Theory as a Framework for Designing and Evaluating Pharmaceutical Risk Mitigation Dissemination and Implementation Strategies” in Risk Management Principles for Devices and Pharmaceuticals: Global Perspectives on the Benefit:Risk Assessment of Medicinal Products, ed. W.K. Sietsema, J. M. Sprafka., eds. Rockville, MD: Regulatory Affairs Professionals Society, 2012. ISBN: 978-0-9829320-3-2.

E-BOOKS

1. **Morrato EH**, Rabin B, Cameron C, Glasgow RE. “Users’ Guide to Dissemination and Implementation in Health for Researchers and Practitioners”. Colorado Research in Implementation Science Program (CRISP), University of Colorado Denver, Anschutz Medical Campus. Published October 2014. www.CRISPebooks.org .
2. **Morrato EH**, Rabin B, Cameron C, Glasgow RE. “Introduction to Pragmatic Clinical Trials”. Colorado Research in Implementation Science Program (CRISP), University of Colorado Denver, Anschutz Medical Campus. Published July 2015. www.CRISPebooks.org .

INVITED BOOK REVIEWS

1. *Textbook of Pharmacoepidemiology Edited by Brian L. Strom and Stephen E. Kimmel* **Elaine H. Morrato** *American Journal of Epidemiology* 2007; doi: 10.1093/aje/kwm215
2. *Wade Hampton Frost, Pioneer Epidemiologist 1880-1938: Up to the Mountain by Thomas M. Daniel.* *American Journal of Epidemiology.* **Elaine H. Morrato** 2005; 162(3): 290-291.

LETTERS TO THE EDITOR

1. **Morrato EH**, Campagna E, Druss BG, Newcomer JW. Authors’ response: How can we produce relevant information for decision makers from small area variation studies? *Pharmacoepidemiology and Drug Safety.* 2011; 20(7):782–783 [Epub] 28 JUN 2011, DOI: 10.1002/pds.2174

TESTIMONY

1. “Input on Issues and Challenges Associated with the Standardization of REMS” Submitted September 13, 2013 to the Federal Register: FDA Notice of Public Hearing and Request for Comments Standardizing and Evaluating REMS, Vol. 78, No. 99, May 22, 2013.
2. On behalf of the Benefit Risk Assessment, Communication, and Evaluation (BRACE) Special Interest Group. “International Society for Pharmacoepidemiology (ISPE) Response to FDA Questions: Standardization and Evaluation of Risk Evaluation and Mitigation Strategies (REMS) – Public Meeting on July 25-26, 2013”. Submitted March 2014 to the Federal Register: FDA Notice of Public Hearing and Request for Comments Standardizing and Evaluating REMS, Vol. 78, No. 99, May 22, 2013.

See: <http://www.regulations.gov/#!documentDetail;D=FDA-2013-N-0502-0042>

RESEARCH REPORTS

1. **Morrato EH**, Campagna E, Fang H, Root ED, Thomas D, Dibert E, Ferre, Stuve P, Parks J, Newcomer JW. “Effectiveness of Invega Sustenna® in a Medicaid Population: Comparing the effectiveness of a long-acting paliperidone palmitate versus oral second generation antipsychotics when used by adult patients with schizophrenia in a real-world clinical environment” for Janssen Scientific Affairs, LLC. May 14, 2012R21
2. **Morrato EH**, Allen RR, Kempe A. “Colorado Children’s Healthcare Access Program (CCHAP): 12-Month Evaluation of the Program (July 1, 2007 – June 30, 2008)” for the Colorado Department of Health Care Policy and Financing. March 19, 2009
3. **Morrato EH**, Allen RR, Kempe A. “Colorado Children’s Healthcare Access Program (CCHAP): Preliminary Evaluation of the Program (July 1, 2007 – December 31, 2007)” for the Colorado Department of Health Care Policy and Financing. October 31, 2008
4. Valuck RJ, Libby AM, **Morrato EH**, Orton H, Allen R. “An evaluation of the FDA warnings on antidepressants and suicidality on patterns of care for depression in U.S. managed care enrollees” for Eli Lilly and Company. November 28, 2006.
5. Valuck RJ, **Morrato EH**, Allen RR. “Atypical Antipsychotic Treatment Patterns in a Multi-State Medicaid Population (1998-2003)” for Ortho-McNeil, Janssen. March 2006.
6. Valuck RJ, **Morrato EH**. “Escitalopram vs. citalopram: a comparison of dosing and titration in community-based clinical practices” for Forest Laboratories. December 2004.

PUBLISHED AND PRESENTED RESEARCH ABSTRACTS

1. Holtrop JS, Ruland S, Diaz S, **Morrato EH**, Jones ES. Using social network analysis to examine the effect of care management program structure on chronic disease communication. Oral presentation at the 44th North American Primary Care Group (NAPCG) Annual Meeting, Colorado Springs, CO, November 12-16, 2016.
2. **Morrato EH**, Campagna EC, Brewer SE. Programmatic Efficiency of a Pharmaceutical Risk Management Program: Outcomes from Diabetes Screening of Adults Receiving Antipsychotics. Poster presentation at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 25-28, 2016.
3. Brewer SE, Campagna EC, **Morrato EH**. Regulatory Considerations for Knowledge, Attitude, and Belief Surveys: A Systematic Review of Physician Survey Response. Poster presentation at the 32nd

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Dublin, Ireland, August 25-28, 2016.

4. **Morrato EH**, Sheridan S, Miller T. Implementation of Appropriate Use of Clinical Preventive Services: Setting a National Research Agenda. Symposium presentation at the Oral presentation at the 2015 *AHRQ Research Conference*, Crystal City, VA. October 6–8, 2015.
5. **Morrato EH**, Campagna E, Brewer S, Dickinson LM, Thomas DSK, Lindrooth R. After a Decade of Risk Communication on Diabetes Risks Associated with Antipsychotic Drugs: Where Do We Stand on Prescriber Attitudes and Behaviors? *Pharmacoepidemiol Drug Saf.* 2015 Aug;24(S1: A760). Oral presentation at the *31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*, Boston, MA. August 22-26, 2015
6. **Morrato EH**, Campagna E, Brewer S, Dickinson LM, Thomas DSK, Lindrooth R. Diabetes Testing for Adults Taking Antipsychotic Drugs: Where To Target Risk Minimization Interventions. *Pharmacoepidemiol Drug Saf.* 2015 Aug;24(S1: A805). Selected “Best Poster” in the Spotlight Poster Session-Benefit Risk Assessment, Communication and Evaluation (BRACE) at the *31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*, Boston, MA. August 22-26, 2015.
7. **Morrato EH**, Campagna EJ, Brewer S, Lindrooth RC, Thomas DSK, Dickinson LM, Dearing JW, Driver R, Druss B, Miller B, Newcomer JW, Parks JJ. Prioritizing Implementation Strategies for Population Health using Market Segmentation: Diabetes Screening for Adults taking Antipsychotics in Missouri Medicaid. Poster presentation at the *7th Annual Conference on the Science of Dissemination and Implementation*, Bethesda, MD. December 8-9, 2014.
8. **Morrato EH**, Rabin B, Proctor J, Cicutto LC, Battaglia C, Lambert-Kerzner A, Leeman-Castillo B, Prahll-Wretling M, Buckley B, Glasgow RE, Kempe A. Bringing it Home: Expanding the Reach and Spread of Dissemination and Implementation (D&I) Training. Poster presentation at the *7th Annual Conference on the Science of Dissemination and Implementation*, Bethesda, MD. December 8-9, 2014.
9. **Morrato EH**, Campagna EJ, Dibert E, Parks J. Diabetes Screening of Adults Receiving Antipsychotics: A U.S. State Survey of Prescribers. presentation at the *29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28, 2013.
10. Garfield LD, Campagna EJ, Nicol GE, Scherrer JF, Ganeshra N, Parks J, **Morrato EH**. Metabolic Risk and Screening in CMHC Patients Starting SGAs in MO Medicaid. Poster presentation at the *29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28, 2013.
11. Wilson AW, Johnson L, Wadwa RP, Maahs D, Hausteine V, Bishop F, **Morrato EH**. “Early Periodontal Disease in Adolescents with Type I Diabetes”. *J Dent Res* Vol 92 (Special Issue A): abstract 340, 2013 (www.iadr.org).
12. Campagna E, Muser E, Newcomer JW, Parks J, **Morrato EH**. "Methodological Considerations in Estimating Drug Adherence for a Long-Acting Injectable Medication". Poster presentation at the *28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Barcelona, Spain, August 23-26, 2012.
13. Root ED, Thomas D, Campagna EJ, Newcomer JW, Parks J, **Morrato EH**. "Geospatial Variation in Drug Utilization and the Potential for Confounding by Geography". Poster presentation at the *28th*

International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 23-26, 2012.

14. Merchant AT, **Morrato EH**, Wadwa RP, Maahs DM, Teles R, Johnson L, Bishop F, Zhang J. “Periodontal Microorganisms in Youth With and Without Type 1 Diabetes”. Poster Presentation at the *American Diabetes Association’s 72nd Scientific Sessions*, Philadelphia, PA, June 8-12, 2012.
15. **Morrato EH**, Campagna E, Parks J, Stuve P, Thomas D, Fang H, Dilbert, Muser E, Newcomer JW. “Characteristics of Medicaid patients initiating paliperidone palmitate compared with oral atypical antipsychotics”. Poster presentation at the *American Psychiatric Association’s 165th Annual Meeting*, Philadelphia, PA, May 5-9, 2012.
16. Newcomer JW, Campagna E, Parks J, Stuve P, Thomas D, Fang H, Dilbert, Muser E, **Morrato EH**. “Drug utilization patterns for paliperidone palmitate in Medicaid patients”. Poster presentation at the *American Psychiatric Association’s 165th Annual Meeting*, Philadelphia, PA, May 5-9, 2012.
17. **Morrato EH**, Dibert E, Parks J, Jones EC, Green M, Tien A. “Linking Drug Prescriber Behaviors to Peer Influence Networks”. Oral presentation at the International Network for Social Network Conference (Sunbelt XXXII), Redondo Beach, CA, March 12-18, 2012.
18. Somme S, Bronsert M, **Morrato EH**, Ziegler MM. “U.S. Prevalence of Paediatric Surgical Procedures”. Oral presentation at the *2011 British Association of Paediatric Surgeons (BAPS) International Congress*, Belfast, Ireland, July 19-22, 2011.
19. Nicol GE, **Morrato EH**, Johnson MC, Campagna EC, Yingling MD, Pham V, Newcomer JW. “Successful Implementation of a Glucose Monitoring Program in a Community Mental Health Setting”. Poster presentation at the 2010 *Institute on Psychiatric Services*, Boston, MA, October 14-17, 2010.
20. **Morrato EH**, Orlando VA, Johnson LR, Wilson AR, Maahs DM, Bishop FK, Dong F, Merchant A, Wadwa RP. “Questions Concerning Periodontal Disease Prevalence in Adolescents with Type 1 Diabetes”. Poster presentation selected as one of the top 100 posters showcased in the Presidents Poster Session and Reception at the *70th Scientific Sessions of the American Diabetes Association*, Orlando, FL June 25-29, 2010.
21. Orlando VA, Johnson LR, Wilson AR, Maahs DM, Wadwa RP, Bishop FK, Dong F, **Morrato EH**. “Oral Health Knowledge and Behaviors among Adolescents with Type 1 Diabetes”. Poster presentation featured in the poster tour entitled “Pediatrics – Type 1 Diabetes – Care and Outcomes” at the *70th Scientific Sessions of the American Diabetes Association*, Orlando, FL June 25-29, 2010.
22. Nicol GE, **Morrato EH**, Johnson MC, Campagna EC, Yingling MD, Pham V, Newcomer JW. “Successful Implementation of a Glucose Monitoring Program in a Community Mental Health Setting”. Poster presentation at the 2010 *American Psychiatric Association Annual Meeting*, New Orleans, LA, May 22-26, 2010.
23. Erickson MA, Barnard JG, **Morrato EH**, Nowels CT, Benefield EM, Hadley-Miller NA, Kempe A. “Management of Surgical Risk in High Risk pediatric Patients: Provider and Family Caregiver Experiences of Spinal Fusion Surgery and Care Program” Poster presentation at the *Annual Meeting of the Pediatric Orthopaedic Society of North America*, May 4-7, 2010, Waikoloa, HI.
24. Erickson MA, Barnard JG, **Morrato EH**, Nowels CT, Benefield EM, Hadley-Miller NA, Kempe A. “Quality of Life for Children with Neuromuscular Scoliosis Two-Years after Spinal Fusion Surgery”

Poster presentation at the *Annual Meeting of the Pediatric Orthopaedic Society of North America*, May 4-7, 2010, Waikoloa , HI.

25. Barnard JG, **Morrato EH**, Benefield EM, Hadley-Miller NA, Kempe A, Erickson MA. "Quality of Life for Children with Neuromuscular Scoliosis", Poster presentation at the *2010 Pediatric Academic Societies' Annual Meeting*, May 1-4, 2010, Vancouver, BC, Canada.
26. Barnard JG, **Morrato EH**, Benefield EM, Hadley-Miller NA, Kempe A, Erickson MA. Quality of life for children with neuromuscular scoliosis. Poster presentation at the *2009 Annual Meeting of the International Society for Quality of Life Research*, New Orleans, LA, October 28-31, 2009.
27. **Morrato EH**, Druss B, Hartung DM, Valuck RJ, Thomas D, Allen RR, Campagna E, Newcomer JW. Determinants of metabolic testing for patients treated with second-generation antipsychotics after the FDA diabetes Warning. Oral presentation at the *25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Providence, RI, August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*. 2009.
28. **Morrato EH**, Nicol G, Druss B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic risk mitigation in children receiving antipsychotics. Poster presentation at the *25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Providence, RI, August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*. 2009.
29. **Morrato EH**, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings on Antipsychotic Drugs and Diabetes. Poster presentation at the *2009 American Psychiatric Association Annual Meeting*, San Francisco, CA, May 16-19, 2009.
30. Barnard JG, Erickson MA, **Morrato EH**, Hadley-Miller NA, Benefield EM, Nowels CT, Kempe A. Managing Surgical Risk and Post-Discharge Needs in Special Needs Children with Neuromuscular Scoliosis: The High-Risk Pathway. Poster presentation at the *2009 Pediatric Academic Societies' Annual Meeting*, Baltimore, MD, May 2-5, 2009.
31. Erickson MA, Miller N, Kempe A, **Morrato EH**, Benefield E. Benton K. Variability in Spinal Surgery Outcomes among Children's Hospitals in the U.S. Oral presentation to be presented at the *2009 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting*, Las Vegas, NV, February 25-28, 2009.
32. Flake C, Johnson L, Orlando V, Bishop F, Wadwa P, Wilson A, Maas, D, **Morrato EH**. Periodontal health status of adolescents with type 1 diabetes. Poster presentation at the *25th Annual Research Day at the School of Dental Medicine*. February 18, 2009. University of Colorado Denver, Aurora, CO.
33. **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic testing after the FDA warning on atypical antipsychotic drugs and diabetes risk. Oral presentation at the *24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. August 17-20, 2008. Copenhagen, Denmark. *Pharmacoepidemiology and Drug Safety*. 2008 17: S266.
34. **Morrato EH**, Partrick D, Sullivan PW, Ghushchyan V, Kempe A. Prevalence of reflux disorders and antireflux medication in U.S. children. Poster to be presented at the *24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. August 17-20, 2008. Copenhagen, Denmark. *Pharmacoepidemiology and Drug Safety*. 2008 17: S204.

35. **Morrato EH**, Erickson M, Beaty B; Benton K; Benefield E, Kempe, A. Variability in surgical outcomes for spinal fusion surgery in U.S. children's hospitals. Oral presentation presented at the Health Services Epidemiology Spotlight Session at the *Society for Epidemiology Research Conference*, June 24-27, 2008, Chicago, IL. *Am J Epidemiol.* 2008; 167(Suppl): S40.
36. Partrick DA, **Morrato EH**, Kempe A, Beaty B, Roach JP, Ziegler MM. National frequency of antireflux procedures and gastrectomy. Analysis of hospital type, patient age, and presence of neurologic impairment. Oral presentation at the *Pacific Association of Pediatric Surgeons 41st Annual Meeting*. June 29-July 3, 2008, Jackson Hole, WY.
37. **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA Consensus Statement on Antipsychotic Drugs and Risk of Diabetes and Dyslipidemia. Poster presented at the *American Diabetes Association's 68th Scientific Sessions*. June 6-10, 2008, San Francisco, CA. *Diabetes.* 2008; 57(Suppl 1): A279.
38. **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Impact of the atypical antipsychotic FDA Warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. Poster to be presented at the *48th Annual NCDEU Meeting*, co-sponsored by the National Institute of Mental Health (NIMH) and the American Society of Clinical Psychopharmacology (ASCP). May 27-30, 2008, Phoenix Arizona.
39. Fox D, **Morrato EH**, Partrick D, Bruny J, Benton K, Kempe A. National trends regarding fundoplication in neurologically impaired children. Poster presented at the *Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting*. Honolulu, HI, May 3-6, 2008.
40. **Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Trends in annual metabolic screening for patients taking second-generation antipsychotic medications. Poster presented at the *161st Annual Meeting of the American Psychiatric Association Annual Meeting*. May 3-8, 2008, Washington, D.C.
41. Benefield E, Erickson MA, **Morrato EH**. Implementing a protocol for high risk children undergoing surgery: How do you make it work? Poster presented at the *18th Annual Convention of the Society for Pediatric Nurses*. April 4-6, 2008, Denver, CO.
42. Partrick DA, **Morrato EH**, Roach JP, Ziegler, MM. The national frequency of gastrointestinal pediatric surgery in hospitalized neonates. Oral presentation presented at the *3rd Annual Academic Surgical Congress*. February 13-15, 2008, Huntington Beach, CA.
43. Banta JE, **Morrato EH**, Lee SW. Diabetes care among Medicaid psychiatric patients. *135th Annual Meeting of the American Public Health Association*. November 3 – 7, 2007, Washington, D.C.
44. **Morrato EH**, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J. Effect of metabolic risk status on atypical antipsychotic treatment choice. *160th Annual Meeting of the American Psychiatric Association*. May 19-24, 2007, San Diego, CA.
45. **Morrato EH**, Curbow B, Nowels C, Feinleib M. Physician sources and perceptions of drug risk communication. *Pharmacoepidemiology and Drug Safety.* 2006;15 (Suppl 1): S189.
46. **Morrato EH**, Feinleib M, Valuck RJ. Changes in liver function testing following the nefazodone boxed warning. *Pharmacoepidemiology and Drug Safety.* 2006;15 (Suppl 1): S139.
47. **Morrato EH**, Feinleib M, Valuck RJ. Characteristics of nefazodone patients receiving baseline liver function testing. *Pharmacoepidemiology and Drug Safety.* 2006;15 (Suppl 1): S139.

48. **Morrato EH**, Newcomer JW, Allen RR, and Valuck RJ. Atypical antipsychotics and diabetes testing: a four-state Medicaid study. *Diabetes*. 2006; 55 (Supplement 1).
49. **Morrato EH**, Newcomer JW, Allen RR, and Valuck RJ on behalf of the Medicaid Pharmacotherapy Research Consortium. Atypical antipsychotics and metabolic screening: a four-state Medicaid study. *159th Annual Meeting of the American Psychiatric Association Annual Meeting*. May 20-25, 2006. Toronto, Canada.
50. RJ Valuck, **EH Morrato**, SL Dodd and RR Allen on behalf of the Medicaid Pharmacotherapy Research Consortium. Antipsychotic utilization: a six-state Medicaid study. *159th Annual Meeting of the American Psychiatric Association Annual Meeting*. Toronto, Canada. May 20-25, 2006.
51. RJ Valuck, **EH Morrato**, SL Dodd and RR Allen on behalf of the Medicaid Pharmacotherapy Research Consortium. Antipsychotic polypharmacy costs: a five-state Medicaid study. *Value in Health*. 2006; 9(3):A70.
52. Valuck RJ, Libby AM, **Morrato EH**, Oquenda MA, Brown H, Gibbons RD. Antidepressant treatment and risk of suicide attempt by adults with major depressive disorder: a propensity-adjusted retrospective cohort study. *Neuropsychopharmacology*. 2005; 30 (Supplement 1): S242.
53. McCollum M, Ellis SE, **Morrato EH**, Ghushchyan V, Sullivan PW. Prevalence of cardiovascular risk factors among people with and without diabetes and CHD. *American College of Clinical Pharmacy Annual Meeting*. San Francisco, CA. October 22-26, 2005.
54. Valuck RJ, **Morrato EH**, Allen R, Dodd S. Atypical antipsychotic treatment patterns in six Medicaid fee-for-service populations. *The 2005 National Medicaid Summit*. Park City, UT. September 29-October 1, 2005.
55. **Morrato EH**, Feinleib M, Valuck RJ. Impact of nefazodone relabeling: changes in prescriber mix and prescribing volume. *Pharmacoepidemiology and Drug Safety*. 2005; 14 (Supplement 1).
56. **Morrato EH**, Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. Prevalence of diabetes with increasing adiposity and inactivity in U.S. adults: the Medical Expenditure Panel Survey 2000-2002. *Diabetes*. 2005; 54 (Supplement 1): A259.
57. **Morrato EH**, Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. Physical activity and diabetes in U.S. adults: the Medical Expenditure Panel Survey 2000-2002. *Diabetes*. 2005; 54 (Supplement 1): A254 .
58. **Morrato EH**, Valuck RJ. Impact of relabeling on nefazodone prescribing: a risk minimization evaluation. *Value in Health*. 2005; 8(3): 395.
59. **Morrato EH**, Staffa JA. Analysis of longitudinal claims data to examine first and second-line use of pemoline (Cylert®). *Value in Health*. 2004; 7(3): 282.
60. **Morrato EH**. Pediatric Drug Labeling Policy: Characteristics of Drugs Granted Exclusivity. *University of Colorado Health Sciences 21st Annual Epidemiology Conference*, February 2003.
61. Kerr, CR, **Morrato, EH**, Humphries, KH et al. Limitations to antiarrhythmic drug use in patients with atrial fibrillation: Insights from the Canadian Registry of Atrial Fibrillation. *North American Society for Pacing and Electrophysiology Conference*, May 2001.

62. Bhattacharyya SK, Tomondy P, Huber D, **Morrato EH**. Resource utilization for side-effects of antiarrhythmic drugs. *DIA 36th Annual Meeting*, June 2000.
63. Bhattacharyya SK, Tomondy P, Huber D, **Morrato EH**. Outpatient resource utilization of patients with atrial fibrillation or flutter related to recurrence and maintenance of normal sinus rhythm. *DIA 36th Annual Meeting*, June 2000.
64. Bhattacharyya SK, **Morrato EH**. Costs of the treatment of side effects of antiarrhythmic drugs in the USA. *International Society for Pharmacoeconomic and Outcomes Research 5th Annual International Meeting*, May, 2000.